Clinical uses of botulinum neurotoxins: current indications, limitations and future developments

Toxins (Basel). 2012 Oct;4(10):913-39. doi: 10.3390/toxins4100913. Epub 2012 Oct 19.

Abstract

Botulinum neurotoxins (BoNTs) cause flaccid paralysis by interfering with vesicle fusion and neurotransmitter release in the neuronal cells. BoNTs are the most widely used therapeutic proteins. BoNT/A was approved by the U.S. FDA to treat strabismus, blepharospam, and hemificial spasm as early as 1989 and then for treatment of cervical dystonia, glabellar facial lines, axillary hyperhidrosis, chronic migraine and for cosmetic use. Due to its high efficacy, longevity of action and satisfactory safety profile, it has been used empirically in a variety of ophthalmological, gastrointestinal, urological, orthopedic, dermatological, secretory, and painful disorders. Currently available BoNT therapies are limited to neuronal indications with the requirement of periodic injections resulting in immune-resistance for some indications. Recent understanding of the structure-function relationship of BoNTs prompted the engineering of novel BoNTs to extend therapeutic interventions in non-neuronal systems and to overcome the immune-resistance issue. Much research still needs to be done to improve and extend the medical uses of BoNTs.

Keywords: Botulinum neurotoxin; clinical indications; future developments; novel applications.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Botulinum Toxins / therapeutic use*
  • Face
  • Humans
  • Hyperhidrosis / drug therapy
  • Neurotoxins / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Skin / drug effects
  • Skin / metabolism
  • Spasm / drug therapy
  • Strabismus / drug therapy
  • Torticollis / drug therapy

Substances

  • Neurotoxins
  • Botulinum Toxins